“Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks’ Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies” (2018) SKIN The Journal of Cutaneous Medicine, 2(S1), p. S16. doi:10.25251/skin.2.supp.16.